RT Journal Article
SR Electronic
T1 Combined pre-dialysis systolic blood pressure and pulse rate assessment for all-cause and cardiovascular mortalities: A nationwide cohort study on patients undergoing haemodialysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.06.30.24309750
DO 10.1101/2024.06.30.24309750
A1 Joki, Nobuhiko
A1 Toida, Tatsunori
A1 Niihata, Kakuya
A1 Inanaga, Ryohei
A1 Nakata, Kenji
A1 Abe, Masanori
A1 Hanafusa, Norio
A1 Kurita, Noriaki
YR 2024
UL http://medrxiv.org/content/early/2024/07/01/2024.06.30.24309750.abstract
AB Background and Aims The prognostic utility of the combined assessment of pre-haemodialysis systolic blood pressure (SBP) and pulse rate (PR) compared with their individual assessment is unclear. This study aimed to determine whether the combined assessment could enhance the prognostic utility in patients on haemodialysis.Methods This nationwide cohort study involved patients undergoing maintenance haemodialysis using the Japanese Renal Data Registry database. Exposure was defined as a combination of SBP and PR. Forty-eight levels of exposure groups were created: SBP (six levels; <100, 100-<120, 120-<140, 140-<160 [reference], 160-<180, and ≥180 mmHg) and PR (eight levels; <50, 50-<60, 60-<70 [reference], 70-<80, 80-<90, 90-<100, 100-<110, and ≥110 per minute). The primary and secondary outcomes were one-year all-cause and cardiovascular mortalities, respectively. Multivariate Cox proportional hazards models were used, and multiplicative interactions were assessed to determine the superiority of the combined model over the individual models. Additive interactions were assessed using relative excess risk due to interactions (RERI).Results The combined model explained mortality and cardiac mortality better than the individual SBP and PR models (P<0.001 and P<0.002, respectively). A lower SBP was associated with a higher risk of all-cause mortality regardless of the PR. Most categories of lower SBP or higher PR vs. the 120-<140 mmHg and 70-<80/min category had positive RERIs. Similar findings were also observed for cardiac mortality.Conclusions The combined assessment of pre-dialysis SBP and PR may help in the simple stratification of patients with excess risks that cannot be identified by individual SBP or PR assessment.Competing Interest StatementToida Tatsunori received consulting fees from Astellas Pharma Inc., and payments and educational events from Torii Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., AstraZeneca K.K., and Nobelpharma Co., Ltd. Ryohei Inanaga received payments for speaking from Astellas Pharma, Inc., Novartis Pharma K.K., and Otsuka Pharmaceuticals. Masanori Abe has received payment for speaking from Novartis Pharma K.K., Otsuka Pharmaceutical. Noriaki Kurita received consulting fees from GlaxoSmithKline K.K. and payments for speaking and educational events from Eisai Co., Ltd., Taisho Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., GlaxoSmithKline K.K., Takeda Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Baxter Corporation.Funding StatementNothing to declare.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Medicine Ethics Committee of the Japanese Society for Dialysis Therapy (No.60) and conducted in accordance with the Declaration of Helsinki.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be available immediately after publication with no end dates. Data will be shared upon reasonable request to the corresponding author with permission from the JRDR investigators. Restrictions apply to the availability of the data analysed in this study to preserve patient confidentiality.